Literature DB >> 11772878

Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia.

Paolo Porcu1, Costanza Emanueli, Maria Kapatsoris, Julie Chao, Lee Chao, Paolo Madeddu.   

Abstract

BACKGROUND: Tissue kallikrein (tK) and vascular endothelial growth factor (VEGF) are potent angiogenic agents. Upregulation of tK or VEGF was documented in animal models of acute ischemia, yet it remains unknown whether these endothelial cell mitogens are overexpressed in chronic peripheral vascular insufficiency. METHODS AND
RESULTS: Circulating tK and VEGF were measured in 36 patients with symptomatic peripheral vascular disease before and after surgical revascularization. In 6 patients without symptoms at rest, tK was assayed after exercise stress test. VEGF levels fell within the normal range in all patients (96+/-11 versus 109+/-13 pg/mL in healthy control subjects, P=NS) and remained unchanged after revascularization. In contrast, tK expression was upregulated in 34 of 36 patients (1107+/-203 versus 85+/-10 pg/mL in control subjects, P<0.05), with no further increase after exercise. Tissue kallikrein levels in the venous effluent of ischemic limbs were found to be positively correlated with the number of angiographically recognizable collateral vessels (P<0.001). Follow-up studies documented reversal of tK upregulation after revascularization (P<0.01), whereas no change was observed in venous samples from untouched legs.
CONCLUSIONS: Induction of tK could represent a compensatory response to chronic arterial insufficiency, attempting to maintain an adequate tissue perfusion. Heterogeneous statement of growth factors may have important implications in reparative and therapeutic angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11772878     DOI: 10.1161/hc0102.101360

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

1.  Factors determining heterogeneity in coronary collateral development: A clinical perspective.

Authors:  Pier D Lambiase; Michael S Marber
Journal:  Exp Clin Cardiol       Date:  2002

2.  Mesenchymal stem cell-based HSP70 promoter-driven VEGFA induction by resveratrol promotes angiogenesis in a mouse model.

Authors:  Young-Bin Chen; Ying-Wei Lan; Tsai-Hsien Hung; Lih-Geeng Chen; Kong-Bung Choo; Winston T K Cheng; Hsuan-Shu Lee; Kowit-Yu Chong
Journal:  Cell Stress Chaperones       Date:  2015-04-10       Impact factor: 3.667

3.  Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement.

Authors:  A Del Rosso; O Distler; A F Milia; C Emanueli; L Ibba-Manneschi; S Guiducci; M L Conforti; S Generini; A Pignone; S Gay; P Madeddu; M Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

4.  Role of human tissue kallikrein in gastrointestinal stromal tumour invasion.

Authors:  P Dominek; P Campagnolo; M H-Zadeh; N Kränkel; M Chilosi; J A Sharman; A Caporali; G Mangialardi; G Spinetti; C Emanueli; M Pignatelli; P Madeddu
Journal:  Br J Cancer       Date:  2010-09-21       Impact factor: 7.640

Review 5.  Regenerative therapies for diabetic microangiopathy.

Authors:  Roberto Bassi; Alessio Trevisani; Sara Tezza; Moufida Ben Nasr; Francesca Gatti; Andrea Vergani; Antonio Farina; Paolo Fiorina
Journal:  Exp Diabetes Res       Date:  2012-03-29

Review 6.  The vascular endothelium and human diseases.

Authors:  Peramaiyan Rajendran; Thamaraiselvan Rengarajan; Jayakumar Thangavel; Yutaka Nishigaki; Dhanapal Sakthisekaran; Gautam Sethi; Ikuo Nishigaki
Journal:  Int J Biol Sci       Date:  2013-11-09       Impact factor: 6.580

7.  Human Urinary Kallidinogenase Promotes Angiogenesis and Cerebral Perfusion in Experimental Stroke.

Authors:  Lijuan Han; Jie Li; Yanting Chen; Meijuan Zhang; Lai Qian; Yan Chen; Zhengzheng Wu; Yun Xu; Jingwei Li
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

8.  Urinary kallidinogenase for the treatment of cerebral arterial stenosis.

Authors:  Liandong Zhao; Ying Zhao; Qi Wan; Haijun Zhang
Journal:  Drug Des Devel Ther       Date:  2015-10-13       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.